Brief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
09/10/2026 11:37
BRIEF-Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data Oct 9 (Reuters) - Alumis Inc. ALMS.O:
ALUMIS ANNOUNCES NEW PHASE 3 DATA DEMONSTRATING ENVUDEUCITINIB RAPIDLY AND DURABLY IMPROVED PSORIASIS BURDEN ACROSS SCALP, ITCH, AND QUALITY OF LIFE MEASURES
ALUMIS - PLANS NDA SUBMISSION FOR ENVUDEUCITINIB IN 4Q 2026
ALUMIS - ONWARD3 SHOWS 54% PASI 100 SKIN CLEARANCE AT WEEK 48 FOR ENVUDEUCITINIB
ALUMIS - OVER 80% OF ONWARD3 PATIENTS MAINTAIN CLEAR OR ALMOST CLEAR SCALP SKIN AT 48 WEEKS
Source text: ID:nGNX6ys8zm
Further company coverage: ALMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial